title: Single acute-dose and repeat-doses toxicity of anti-HIV-1 PNA TAR-penetratin conjugate after intraperitoneal administration to mice.
abstract: Polyamide (peptide) nucleic acids conjugated with membrane-penetrating peptide are potential antisense therapeutic agents because of their unique chemical properties, high target specificity, and efficient cellular uptake. However, studies of their potential toxicity in animal models are lacking. In this study, we evaluated the toxicity of the response of Balb/C mice to anti-HIV-1 PNA TAR-penetratin conjugate targeted against the transactivation response (TAR) element of HIV-1 LTR. A single i.p. dose of 600 mg/kg of body weight was lethal, killing all mice within 72 hours. However, death did not occur after single doses of 100 and 300 mg/kg, although all mice experienced initial and transitory diarrhea and loss of agility. Repeated daily doses of 10, 30, and 100 mg/kg were well tolerated by mice during 8 days of treatment, although daily doses of 100 mg/kg caused diarrhea during the first 4 days of treatment. During 8 weeks of follow-up, mice fully recuperated. Serositis was observed in the spleens, livers, and kidneys at the ninth day of treatment, but not after the follow-up period. Necropsies, clinical chemistry studies, and hematological parameters demonstrated normal function of the major organs and no irreversible damage to the mice. These observations indicate that the PNA-peptide conjugate would be nontoxic at probable therapeutic doses and thus support its therapeutic potential as an antisense drug.
authors.affiliation: Department of Biochemistry and Molecular Biology, UMDNJ-New Jersey Medical School, Newark, NJ 07103, USA.
authors.forename: Binay
authors.initials: B
authors.lastname: Chaubey
authors.forename: Snehlata
authors.initials: S
authors.lastname: Tripathi
authors.forename: Virendra N
authors.initials: VN
authors.lastname: Pandey
mesh_terms: D000818:Animals; D001853:Bone Marrow / Q000473:pathology; D002352:Carrier Proteins / Q000008:administration & dosage / Q000737:chemistry*; D057846:Cell-Penetrating Peptides; D004305:Dose-Response Relationship, Drug; D016325:HIV Long Terminal Repeat; D015497:HIV-1 / Q000235:genetics*; D007274:Injections, Intraperitoneal; D007668:Kidney / Q000473:pathology; D008099:Liver / Q000473:pathology; D008297:Male; D013058:Mass Spectrometry; D051379:Mice; D008807:Mice, Inbred BALB C; D020135:Peptide Nucleic Acids / Q000008:administration & dosage / Q000737:chemistry*; D013154:Spleen / Q000473:pathology
chemical_list: D002352:Carrier Proteins; D057846:Cell-Penetrating Peptides; D020135:Peptide Nucleic Acids; C414409:penetratin